Avian Influenza Vaccine Market Size, Share, Growth Analysis, By Strain(H5, H7, and H9), By Application(Chicken, Turkey, and Goose & Duck), By Region - Industry Forecast 2024-2031

Global Avian Influenza Vaccine Market size was valued at USD 140.0 Billion in 2022 and is poised to grow from USD 145.88 Billion in 2023 to USD 202.74 Billion by 2031, growing at a CAGR of 4.2% in the forecast period (2024-2031).

Avian influenza is caused by avian influenza virus type A, which is found in waterfowl and subsequently causes disease in domestic poultry. The virus was first detected in China. The Asian H5N1 version was discovered the following year in an outbreak in Hong Kong and has since spread to Europe, Asia, North and South America, Africa and the Middle East Avian influenza can be classified as a pandemic greater virus and less virulent based on its molecular structure. Depending on the virus, the viruses are classified into H5N1, H7N3, H7N7, H7N9, and H9N2. In addition, type A virus of subtype H5N1 is currently considered to be the most pathogenic avian influenza virus under investigation. Bird flu is known to be transmitted to humans through nose and mouth breathing. Classification of avian influenza vaccines includes H5 avian influenza vaccine, H7 avian influenza vaccine, and H9 avian influenza vaccine. Among manufacturers, China stands out as the largest supplier of avian influenza vaccine, with the US being the largest supplier.

There were 633,323 adults in the US. with cirrhosis, or about 0.27% of the population. Sixty-nine percent said they did not suspect liver disease. It was higher among non-Hispanic blacks, Mexican Americans who were poor and had less than 12th grade education. Diabetes mellitus, alcohol abuse, hepatitis C and B, male gender, older age, and cirrhosis were independently associated, with 53.5% accounting for the proportion of the population due to viral hepatitis (mostly hepatitis C), diabetes mellitus, and excessive alcohol consumption every two years in cirrhosis. There was a mortality rate of 26.4, compared with 8.4% in characteristic-matched controls.